1. Dec 2006 NCI: Advanced Technologies workshop NCI: AT RO: SATURDAY Opportunities and Priorities  Presentations: 15 min or less  Breakout sessions  Summary & Conclusions & Feedback

2. Dec 2006 NCI: Advanced Technologies workshop BREAKOUT GROUPS  Group 1 - Head (Brain, H&N & Peds)  Group 2 - Trunk (Breast, Lung & Upper Abd)  Group 3 - Pelvis (Prostate, Cervix & Colon-Rectum)

3. Dec 2006 NCI: Advanced Technologies workshop GROUP 1  Bharat Mittal: Leader  Kian Ang  Wally Curran  Tom Delaney  Jonathan Farr  Jim Galvin  Eric Hall  Ed Halperin  Larry Kun  Minesh Mehta  Tom Merchant

4. Dec 2006 NCI: Advanced Technologies workshop GROUP 2  Ted Deweese : Leader  Michael Baumann  Hank Choy  Joseph Deasy  Beryl McCormick  Nancy Mendenhall  Jatinder Palta  James Purdy  Randy Ten Haken  Allan Thornton  Jim Cox  Radhe Mohan

5. Dec 2006 NCI: Advanced Technologies workshop GROUP 3  Mary Gaspodarowicz & Jeff Michalski: Leaders  Chuck Enke  Thomas Fitzgerald  David Jaffray  David Gaffney  Karin Haustermans  Cliff Ling  Howard Sandler  Bill Shipley  Anurag Singh  Jerry Slater  Chris Willet

6. Dec 2006 NCI: Advanced Technologies workshop My Take  Photons, Protons  IMRT, SRS, SBRT, IGRT  Quality Assurance  Image guidance  Lung cancer  Prostate cancer  Head & Neck Cancer  Peds

7. Dec 2006 NCI: Advanced Technologies workshop GUIDELINES  Timer, Scribe and Presenter  Limit comments to 2 minutes or less  Try to have everybody voice opinions  Please allow everybody around the table to voice opinions at least once before commenting second time, so on so forth  Discussion and formulation: 120 min.  Summary and mock presentation among your group:30 min.

8. Dec 2006 NCI: Advanced Technologies workshop KEY QUESTION 1  The raison d’etre for the advanced technologies is to increase the dose to the cancer without increasing toxicity, or deliver the same dose as conventional technology but with less toxicity. QUESTION: In which cancers is there the most pressing need for new technology for increasing the dose or decreasing the toxicity?

9. Dec 2006 NCI: Advanced Technologies workshop KEY QUESTION 2  Demonstrating improved ANTICIPATED dose distributions (in-silico or in phantoms) only generates the hypothesis that a new technology may be superior. To prove that hypothesis, we must demonstrate - by controlled clinical trials - a clinically meaningful increase in survival and/or decrease in toxicity. QUESTION: What clinical trials are the most important for demonstrating a meaningful benefit to patients?

10. Dec 2006 NCI: Advanced Technologies workshop KEY QUESTION 3  Demonstrating improved ACTUAL dose distribution in the patient could be useful in phase I/II trials. QUESTION: What technological developments are required for demonstrating ACTUAL dose distribution in-vivo?

11. Dec 2006 NCI: Advanced Technologies workshop KEY QUESTION 4  Other clinical or biological intermediate end-points may be useful in clinical trials. QUESTION: What might those intermediate end-points be (and what lessons have we learned regarding their pitfalls from PSA, etc?)

12. Dec 2006 NCI: Advanced Technologies workshop SUCCESSFUL MEETING 1.Do we clearly understand the objectives of the meeting? 2.Are we focusing on relevant facts and keeping to the original objectives? 3.Are we using our time efficiently? 4.Are we working towards solutions and results?

13. Dec 2006 NCI: Advanced Technologies workshop SUMMARY, REC. & FEEDBACK  Each group presentation: 10 -15 min  Q & A: 15 min  Feedback:  Overall impression  Best part of the workshop  What would you do to improve this kind of workshop?  Rate the performance of this group